Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 68

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 68
---
 we
entered into a securities purchase agreement, providing for the issuance in a registered direct offering of 7,000,000 Common Shares, at
a purchase price of $0.25 per share (the “March Purchase Agreement”). The offering closed on March 22, 2024. In addition,
pursuant to the March Purchase Agreement, the investors received unregistered warrants to purchase up to an aggregate of 3,500,000 Common
Shares at an exercise of $0.25 per share in a concurrent private placement (the “Common Warrants”). The Common Warrants were
immediately exercisable upon issuance and will expire five years following the date of issuance. The March Purchase Agreement contains
customary representations and warranties and agreements of the Company and the investors and customary indemnification rights and obligations
of the parties. Pursuant to the March Purchase Agreement, we agreed not to enter into any agreement to issue or announce the issuance
or proposed issuance of any Common Shares or Common Share equivalents for a period of 45 days following the closing of the offering, subject
to certain customary exceptions. We have also agreed that from the date of the March Purchase Agreement until one year after the closing
date of the offering, that we shall not enter into an agreement to effect any issuance by us or any of our subsidiaries of Common Shares
or Common Share equivalents (or a combination of units thereof) involving a variable rate transaction. The offering resulted in gross
proceeds to us of $1,750,000. We intend to use the net proceeds from the offering for working capital and general corporate purposes.

On June 28, 2024, we
entered into a securities purchase agreement providing for the issuance in a registered direct offering of 81,944 Common Shares at a purchase
price of $9.60 per share. In addition, the investors in the offering received unregistered warrants to purchase up to an aggregate of
81,944 Common Shares at an exercise of $9.60 per share in a concurrent private placement. The common warrants were immediately exercisable
upon issuance and expire five years following the date of issuance. The agreement includes customary representations, warranties,
and indemnification provisions. We agreed not to issue or announce the issuance of any Common Shares or equivalents for 15 days post-closing,
with certain exceptions, and not to engage in variable rate transactions for one-year post-closing. The offering generated gross proceeds
of approximately $786,660.

On September 16, 2024,
we